Virtual Library

Start Your Search

Yoo-Kang Kwak



Author of

  • +

    P2.16 - Treatment of Early Stage/Localized Disease (Not CME Accredited Session) (ID 965)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P2.16-04 - Prognostic Value of Lymphovascular Invasion and Its Effect on Patterns of Recurrence in T1-3N0 Non-Small Cell Lung Cancer (ID 13180)

      16:45 - 18:00  |  Author(s): Yoo-Kang Kwak

      • Abstract
      • Slides

      Background

      The purpose of this study is to clarify the prognostic value of lymphovascular invasion (LVI) in patients with surgically resected T1-3N0 non-small cell lung cancer (NSCLC) according to the eighth edition of the TNM Classification of the American Joint Committee on Cancer (AJCC).

      a9ded1e5ce5d75814730bb4caaf49419 Method

      A total of 442 NSCLC patients who received curative surgery and were confirmed with pathologic T1-3N0 between March 2000 and August 2015 were reviewed. The pathological stages were re-evaluated according to the eighth edition of the TNM Classification of the AJCC.

      4c3880bb027f159e801041b1021e88e8 Result

      The 5-year recurrence-free survival (RFS) rate for total cohort was 69.7%, and the 5-year overall survival (OS) rate was 78.0%. LVI was present in 89 patients (19.9%). The presence of LVI decreased the 5-year RFS rate significantly (47.5% vs. 72.3%, p < 0.001) and the 5-year OS rate (62.5% vs. 81.1%, p < 0.001). The differences between LVI group and non-LVI group were more remarkable in T2a-bN0 staged patients compared with T1a-c staged patients (T1a-c patients: 63.6% vs. 78.0%, p = 0.004; T2a-b patients: 31.7% vs. 64.9%, p = 0.027, respectively). Multivariate analysis revealed that the presence of LVI was a significant predictor for RFS (p < 0.001) but an insignificant factor for OS. In T2a-bN0 staged patients, the 5-year OS rate was significantly lower in patients with LVI than in patients without LVI (50.0% vs. 74.4%, p = 0.045), whereas T1a-c staged patients did not show a significant difference in 5-year OS according to the presence of LVI (p = 0.196).

      8eea62084ca7e541d918e823422bd82e Conclusion

      LVI is a significant associated factor for RFS in patients with stage T1-3N0 NSCLC. Prognostic impact of LVI is more remarkable in patients with more than T2N0 stage compared to patients with the T1N0 disease.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.